{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:02Z","timestamp":1791559442959,"version":"4.3.4"},"reference-count":40,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13251","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:26:27Z","timestamp":1785302787000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Immune\u2011mediated liver injury caused by checkpoint inhibitors: A case series and review of the literature"],"prefix":"10.3892","volume":"32","author":[{"given":"Maria","family":"Kyrkasiadou","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kyriazoglou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsantis","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Economopoulou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kavourakis","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roubini","family":"Zakopoulou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Pantazopoulos","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Boulouta","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Moutafi","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Gavrielatou","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Foukas","sequence":"additional","affiliation":[{"name":"Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menelaos","family":"Samaras","sequence":"additional","affiliation":[{"name":"Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Palialexis","sequence":"additional","affiliation":[{"name":"Second Department of Radiology, Interventional Radiology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Psyrri","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Oncology Unit, Attikon University Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"key20260922084514_b1-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"180","key":"key20260922084514_b2-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"102514","key":"key20260922084514_b3-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J Autoimmun"},{"key":"key20260922084514_b4-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"key20260922084514_b5-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: A review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"key20260922084514_b6-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260922084514_b7-ETM-32-4-13251"},{"key":"key20260922084514_b8-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"key20260922084514_b9-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"key20260922084514_b10-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"2023","key":"key20260922084514_b11-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive biomarkers of immune checkpoint inhibitors-related toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"key20260922084514_b12-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors","volume":"40","author":"Riveiro-Barciela","year":"2020","journal-title":"Liver Int"},{"issue":"779691","key":"key20260922084514_b13-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"issue":"100851","key":"key20260922084514_b14-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"key20260922084514_b15-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.14218\/JCTH.2022.00105","article-title":"Immunotherapy-induced hepatotoxicity: A review","volume":"10","author":"Da Cunha","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"key20260922084514_b16-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"issue":"25","key":"key20260922084514_b17-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03858-4","article-title":"Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database","volume":"74","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"key20260922084514_b18-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","volume":"149","author":"Miah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20260922084514_b19-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1007\/s12072-025-10783-w","article-title":"Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: A retrospective analysis based on clinical study and real-world data","volume":"19","author":"Wang","year":"2025","journal-title":"Hepatol Int"},{"key":"key20260922084514_b20-ETM-32-4-13251","doi-asserted-by":"crossref","first-page":"171","DOI":"10.46883\/ONC.2020.3405.0171","article-title":"Immune-related adverse events involving multiple organ sites in a patient treated with nivolumab plus ipilimumab","volume":"34","author":"Remolina-Bonilla","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"key20260922084514_b21-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20260922084514_b22-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"key20260922084514_b23-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related adverse events and anti-tumor efficacy: Real-world data on various solid tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"1077468","key":"key20260922084514_b24-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"key20260922084514_b25-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"key20260922084514_b26-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"issue":"795","key":"key20260922084514_b27-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040795","article-title":"The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: From pathogenesis to multidisciplinary management","volume":"16","author":"Lasagna","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20260922084514_b28-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"488","DOI":"10.15403\/jgld-5045","article-title":"Clinical and pathological features of immune checkpoint inhibitor-induced liver injury in comparison with drug-induced liver injury and autoimmune hepatitis","volume":"32","author":"Sunago","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"issue":"9242","key":"key20260922084514_b29-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88824-1","article-title":"Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease","volume":"11","author":"Hagiwara","year":"2021","journal-title":"Sci Rep"},{"key":"key20260922084514_b30-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"issue":"47","key":"key20260922084514_b31-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0532-1","article-title":"Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"e008074","key":"key20260922084514_b32-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","journal-title":"J Immunother Cancer"},{"key":"key20260922084514_b33-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20260922084514_b34-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"e14609","key":"key20260922084514_b35-ETM-32-4-13251","article-title":"Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience","volume":"42 (16 Suppl)","author":"Wu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"217241","key":"key20260922084514_b36-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217241","article-title":"Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions","volume":"604","author":"Gang","year":"2024","journal-title":"Cancer Lett"},{"issue":"e000604","key":"key20260922084514_b37-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"hyaf200","key":"key20260922084514_b38-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf200","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: A review","author":"Mizuno","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"730320","key":"key20260922084514_b39-ETM-32-4-13251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"key20260922084514_b40-ETM-32-4-13251","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:45:19Z","timestamp":1790055919000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,29]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13251","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}